Venaxis plans to expand its business through its recent acquisition of BiOptix Diagnostics, a medical device company.

Venaxis has acquired approximately 98% of BiOptix’s voting shares for 14% of the former’s post-deal outstanding common shares.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

"The transaction will enable Horizon Pharma to expand its presence into European and other international markets."

M Pharmaceutical announced to expand its business into women’s health market by acquiring an undisclosed company with an FDA-approved product.

The acquirer is a clinical-stage company that develops technologies for obesity and weight management, whereas the target company is a private pharmaceutical company.

Horizon Pharma has entered a definitive agreement to acquire all outstanding and issued shares of Raptor Pharmaceutical for a purchase consideration of $800m, which is expected to be completed in November.

The transaction will enable Horizon Pharma to expand its presence into European and other international markets, strengthen its business revenue across orphan, rheumatology and primary care, and focus on rare diseases.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact